ExoNeuglia Overview
- Year Founded
-
2022
- Status
-
Private
- Latest Deal Type
-
Series A1
- Investors
-
3
ExoNeuglia General Information
Description
Developer of nervous system-related stem cell drugs intended to treat demyelinating diseases. The company uses induced pluripotent stem cell technology to develop medicines to treat demyelinating diseases, helping patients with loss of myelin in the nervous system and conditions such as spinal cord injury, multiple sclerosis, Guillain-Barré syndrome, neuromyelitis optica, etc.
Contact Information
Website
www.exoneuglia.comCorporate Office
- Room 403, 4th Floor, Building M2, 2.5 Industrial Park, No. 88 Dongchang Road
- Suzhou Industrial Park, Suzhou Area, China Pilot Free Trade Zone
- Suzhou, Jiangsu 215000
- China
Corporate Office
- Room 403, 4th Floor, Building M2, 2.5 Industrial Park, No. 88 Dongchang Road
- Suzhou Industrial Park, Suzhou Area, China Pilot Free Trade Zone
- Suzhou, Jiangsu 215000
- China
ExoNeuglia Timeline
ExoNeuglia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A1) | 06-Aug-2025 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 18-Jul-2024 | Completed | Generating Revenue | |||
| 1. Seed Round | 08-Dec-2022 | $7.02M | $7.02M | Completed | Startup |
ExoNeuglia Patents
ExoNeuglia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025107757-A1 | In vitro preparation method for medial ganglionic eminence progenitor cells and gaba interneurons | Inactive | 20-Nov-2023 | ||
| WO-2025008000-A1 | Culture medium and method for efficiently inducing muscle stem cells | Inactive | 05-Jul-2023 | ||
| EP-4741496-A1 | Method for reprogramming human somatic cells into induced pluripotent stem cells | Pending | 04-Jul-2023 | ||
| EP-4741496-A4 | Method for reprogramming human somatic cells into induced pluripotent stem cells | Pending | 04-Jul-2023 | ||
| US-20260132384-A1 | Method for reprogramming human somatic cells into induced pluripotent stem cells | Pending | 04-Jul-2023 | C12N5/0696 |
ExoNeuglia Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ascentage Pharma | Corporation | Minority | ||
| Grains Valley Venture Capital | Venture Capital | Minority | ||
| Redhill Capital | Growth/Expansion | Minority |
ExoNeuglia FAQs
-
When was ExoNeuglia founded?
ExoNeuglia was founded in 2022.
-
Where is ExoNeuglia headquartered?
ExoNeuglia is headquartered in Suzhou, China.
-
What industry is ExoNeuglia in?
ExoNeuglia’s primary industry is Drug Discovery.
-
Is ExoNeuglia a private or public company?
ExoNeuglia is a Private company.
-
What is ExoNeuglia’s current revenue?
The current revenue for ExoNeuglia is .
-
How much funding has ExoNeuglia raised over time?
ExoNeuglia has raised $7.02M.
-
Who are ExoNeuglia’s investors?
Ascentage Pharma, Grains Valley Venture Capital, and Redhill Capital have invested in ExoNeuglia.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process